Skip to content
AnalystLens

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 4, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed November 4, 2024
Period End
November 4, 2024
Security
VRTX
In the record · 2016–202610-K1110-Q328-K100

VRTX filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 100 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Oct ’17Oct ’17
  2. Leadership change8-K · Apr ’20Apr ’20
  3. Material agreement8-K · Jul ’22Jul ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed November 4, 2024. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals reported third quarter 2024 results on November 4, 2024, with product revenue of $2.77 billiona, up 12% year over year, driven primarily by TRIKAFTA/KAFTRIO (up to $2.59 billion from $2.27 billion).

U.S. product revenue grew 10% to $1.71 billionb and ex-U.S. revenue grew 14% to $1.06 billion. The company raised its full-year 2024 product revenue guidance to $10.8–$10.9 billion from $10.65–$10.85 billion, while keeping its expense and acquired IPR&D guidance unchanged. GAAP net income was $1.0 billion ($4.01 diluted EPS) and non-GAAP net income was $1.1 billion ($4.38 diluted EPS), both roughly flat with Q3 2023 as higher R&D and SG&A spending offset revenue growth.

Full-year 2024 results are heavily distorted by the $4.4 billionc Alpine Immune Sciences acquisition-related IPR&D charge taken in Q2 2024, which drove nine-month GAAP net loss to $1.45 billion. Cash, cash equivalents and marketable securities fell to $11.2 billion from $13.7 billion at year-end 2023, reflecting the Alpine cash consideration and share repurchases. Investors should focus on the pipeline and launch catalysts: an FDA PDUFA date of January 2, 2025 for vanzacaftor triple in CF, and a PDUFA date of January 30, 2025 for suzetrigine in moderate-to-severe acute pain.

Three programs (suzetrigine in DPN, povetacicept in IgAN, and VX-880 in T1D) advanced to Phase 3 during the quarter. The press release is furnished under Item 2.02 rather than filed, so its contents are not subject to Section 18 liability unless specifically incorporated by reference into another filing.

02—Key points

Key Highlights

  1. Q3 2024 product revenue of $2.77 billion, up 12% year over year; TRIKAFTA/KAFTRIO contributed $2.59 billion.
  2. Full-year 2024 product revenue guidance raised to $10.8–$10.9 billion from $10.65–$10.85 billion.
  3. Q3 2024 GAAP net income of $1.05 billion ($4.01 diluted EPS) versus $1.04 billion ($3.97) in Q3 2023; non-GAAP diluted EPS of $4.38 versus $4.08.
  4. Nine-month GAAP net loss of $1.45 billion, driven by a $4.54 billion acquired IPR&D charge that includes the $4.4 billion Alpine Immune Sciences acquisition charge.
  5. Cash, cash equivalents and marketable securities declined to $11.2 billion from $13.7 billion at December 31, 2023.
  6. Two FDA PDUFA dates in early 2025: vanzacaftor triple (January 2, 2025, Priority Review) and suzetrigine for acute pain (January 30, 2025, Priority Review).
  7. Three programs advanced to Phase 3 in the quarter: suzetrigine in DPN, povetacicept in IgAN, and VX-880 in T1D.

03—Questions

Frequently Asked Questions

  1. Did Vertex's core business grow in the third quarter of 2024?

    Yes. Product revenue rose 12% to $2.77 billion, with U.S. revenue up 10% and ex-U.S. revenue up 14%. Growth was driven mainly by TRIKAFTA/KAFTRIO, which generated $2.59 billion in the quarter, compared with $2.27 billion a year earlier.

  2. Why did Vertex report a large net loss for the first nine months of 2024?

    The loss stems from a $4.54 billion acquired IPR&D expense, primarily the $4.4 billion charge related to the Alpine Immune Sciences acquisition recorded in Q2 2024. Excluding this non-cash-like charge, underlying profitability remained strong, as shown by non-GAAP net income. Full-year non-GAAP results exclude this charge.

  3. Is Vertex's full-year revenue outlook improving?

    Yes. The company raised its 2024 product revenue guidance to $10.8–$10.9 billion, up from $10.65–$10.85 billion. Expense guidance and acquired IPR&D guidance were left unchanged.

  4. What are the near-term catalysts investors should watch?

    The FDA target action dates are January 2, 2025 for once-daily vanzacaftor triple in CF patients 6 years and older, and January 30, 2025 for suzetrigine in moderate-to-severe acute pain. Both received Priority Review. Vertex also expects initial suzetrigine Phase 2 data in lumbosacral radiculopathy by year-end 2024.

  5. How has Vertex's cash position changed, and why?

    Cash, cash equivalents and marketable securities fell to $11.2 billion at September 30, 2024, from $13.7 billion at December 31, 2023. The decline reflects cash paid for Alpine Immune Sciences and share repurchases, partially offset by operating cash flow.

04—Continue

← View all 8-K filings